Camlipixant

A medication under investigation for the treatment of chronic cough

Camlipixant
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Camlipixant is an investigational medication being studied for its potential use in the treatment of chronic cough. It is a selective antagonist of the P2X3 receptor, which is implicated in the cough reflex pathway.

Mechanism of Action

Camlipixant works by selectively inhibiting the P2X3 receptor, a type of purinergic receptor that is activated by adenosine triphosphate (ATP). The P2X3 receptor is found on sensory neurons and is involved in the transmission of signals that can lead to the sensation of cough. By blocking this receptor, camlipixant may reduce the frequency and severity of coughing episodes in patients with chronic cough.

Clinical Development

Camlipixant is currently undergoing clinical trials to evaluate its safety and efficacy in patients with chronic cough. These trials are designed to assess the drug's ability to reduce cough frequency and improve quality of life for patients who suffer from this condition.

Phase I Trials

In early-phase clinical trials, camlipixant was tested in healthy volunteers to determine its safety profile and pharmacokinetics. These studies helped establish the appropriate dosing regimen for subsequent trials.

Phase II Trials

Phase II trials focused on patients with chronic cough, assessing the drug's efficacy in reducing cough frequency compared to placebo. Preliminary results have shown promise, with many patients experiencing a significant reduction in cough frequency.

Phase III Trials

Camlipixant is currently in Phase III trials, which are larger studies designed to confirm its efficacy and monitor side effects in a broader patient population. These trials are critical for determining whether camlipixant will be approved for clinical use.

Potential Side Effects

As with any medication, camlipixant may cause side effects. Commonly reported side effects in clinical trials include dysgeusia (altered taste perception), nausea, and headache. The safety profile of camlipixant continues to be monitored as clinical trials progress.

Future Directions

If camlipixant proves to be effective and safe, it could become a valuable treatment option for patients with chronic cough, particularly those who have not responded to other therapies. Ongoing research is also exploring the potential use of P2X3 antagonists in other conditions where sensory neuron activation plays a role.

Related Pages

• Chronic cough
• Purinergic receptor
• Adenosine triphosphate